Abstract 347P
Background
De novo brain metastases occur frequently in NSCLC. Untreated brain metastases are an exclusion criteria for most clinical trials whilst local therapies administered at the time of diagnosis may confound radiological response assessment. The intracranial activity of first line chemoimmunotherapy in this setting is uncertain, therefore further data on optimal treatment sequencing are needed.
Methods
Patients with wild-type NSCLC and de novo brain metastases receiving 1st line chemoimmunotherapy or single agent immunotherapy were selected from clinical databases from three institutions. A composite time-to event (TTE) outcome of intracranial disease progression, death or need for local therapy to brain metastases was calculated as a surrogate for intracranial disease progression.
Results
A total of 68 patients were included. Patients were predominantly male (59%), 1 (61%) or 0 (28%), symptomatic (50%) with an adenocarcinoma (90%). The PD-L1 TPS was <1% (37%), 1-49% (17%) and >50% (46%) respectively. Surgery (26%) or upfront radiotherapy (43%) were performed prior to systemic therapy, with 45% proceeding to upfront systemic therapy alone (best intracranial response CR 2/68, PR 8/68, SD 10/68, PD 2/68, NE 9/68). Sixty-nine percent of patients received chemoimmunotherapy and 31% single agent pembrolizumab. At a median follow-up of 20.7 months, OS was 15 months and the median intracranial TTE was 7.3 months. Subgroup analysis did not reveal any significant difference in TTE when patients were stratified according to the presence of brain metastasis symptoms, number of brain metastases or TPS, despite a trend towards significance (p=0.1) in patients who received radiotherapy.
Conclusions
These data suggest that clinical prognostic factors such as PD-L1 status, number of brain metastases or symptoms at baseline are not predictive of intracranial response to chemoimmunotherapy or immunotherapy alone, however the trend towards improved TTE with upfront local treatment may identify patients in whom this treatment sequence is optimal. This warrants further investigation in a larger patient cohort or a prospective trial of treatment sequence.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Itchins: Financial Interests, Personal, Advisory Board: Roche, MSD. M. Boyer: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Advisory Role: MSD, AstraZeneca, Bristol Myers Squibb, Janssen; Financial Interests, Personal, Research Grant: MSD, Pfizer, Boehringer Ingelheim, Lilly, Roche, AstraZeneca, Bristol Myers Squibb, Amgen, Ascentage Pharma, Novartis, Merck Serono; Financial Interests, Personal, Sponsor/Funding: MSD, Genentech/Roche. N. Pavlakis: Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, MSD, Merck, BMS, AstraZeneca, Takeda, Pfizer, Roche, Amgen, BeiGene, Novartis, AllVascular; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheim, Pfizer, Roche, Takeda, Pierre-Fabre; Financial Interests, Institutional, Funding: Bayer, Pfizer, Roche. S.C. Kao: Financial Interests, Personal, Advisory Board: Roche, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
333P - Efficacy and safety of immune checkpoint inhibitors alone or combined with chemotherapy in pulmonary sarcomatoid carcinoma
Presenter: Hiroyasu Kaneda
Session: Poster viewing 05.
334P - Patient-reported outcomes with cemiplimab versus chemotherapy in advanced non-small cell lung cancer (aNSCLC): Geographic region subgroups in EMPOWER-Lung 1
Presenter: Gwo Fuang Ho
Session: Poster viewing 05.
335P - Real-world data of first-line treatment with pembrolizumab for non-small cell lung cancer with high PD-L1 expression (HOT/NJLCG2001)
Presenter: Hiroshi Yokouchi
Session: Poster viewing 05.
336P - Spatial characterisation of immune microenvironment in malignant pleural mesothelioma
Presenter: Dmitrii Shek
Session: Poster viewing 05.
337P - Association of clinical and molecular factors with immune checkpoint inhibitors efficacy in advanced non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Feng Li
Session: Poster viewing 05.
338P - Anti PD1 is superior to anti PDL1 when combined with chemotherapy in first-line treatment for metastatic non-small cell lung cancer (mNSCLC): A network meta-analysis
Presenter: Joe Wei
Session: Poster viewing 05.
339P - Analysis of first- and second-line immunotherapy efficacy in metastatic non-small cell lung cancer with low PD-L1 expression
Presenter: Charlotte McKay
Session: Poster viewing 05.
341P - Cost-effectiveness analysis of first-line atezolizumab for patients with stage IV non-small cell lung cancer whose tumours have a high-programmed death ligand 1 expression in Thailand
Presenter: Kankamon Kittrongsiri
Session: Poster viewing 05.
342P - Prognostic implications of PD-L1 co-expression among Filipino EGFR MT mNSCLC
Presenter: Herdee Gloriane Luna
Session: Poster viewing 05.